SASKATOON – Iotron Medical Inc. (Iotron) and Canadian Isotope Innovations Corp. (CIIC) are pleased to announce a collaboration to produce the radioisotope copper-67 (Cu-67) for new cancer therapies. This investment will increase the production capacity of the CIIC-operated facilities in Saskatoon, making Cu-67 more widely available to international cancer researchers. Iotron Medical, a spin-out business […]
READ MORE
TORONTO – August 24, 2021 – Niagara Energy Products (NEP), a leader in the field of manufacturing radiation shielded containment vessels for isotopes and nuclear contaminated waste, has joined the Canadian Nuclear Isotope Council (CNIC). NEP has a long and storied history in Canada, with three large manufacturing plants in Ontario, providing high-quality jobs in […]
READ MORE
Women in Nuclear (WiN) Canada, an association that has been working to support the objectives of WiN Global by emphasizing and supporting the role that women can and do have in addressing public concerns about nuclear energy and the application of radiation and nuclear technology has signed a partnership with the Canadian Nuclear Isotope Council […]
READ MORE
McMaster University and Promation have signed a Memorandum of Understanding (MoU) to work together to bring a new medical isotope technology developed at McMaster to the marketplace. At the center of this collaboration is a new technology for producing lutetium-177 (Lu-177), an increasingly sought-after medical isotope. Clinical trials have shown that Lu-177-based drugs have tremendous […]
READ MORE
TORONTO – May 12 , 2021 –The Canadian Nuclear Isotope Council (CNIC) and the Local Organizing Committee of the 11th International Conference on Isotopes (11ICI) have entered into a Memorandum of Understanding to co-promote and support the conference’s success in 2022. The 11ICI will be hosted by Sylvia Fedoruk Canadian Centre for Nuclear Innovation in […]
READ MORE
(Ottawa, Ontario – May 10, 2021) – BWXT Medical Ltd. (BWXT Medical) announced today that it has entered into a new long-term, mutually exclusive agreement to manufacture TheraSphere™ Y-90 Glass Microspheres for Boston Scientific, a leading global medical device company. Developed for the treatment of patients with hepatocellular carcinoma (HCC), TheraSphere treatment is comprised of millions […]
READ MORE
